COSCIENS Biopharma approved a share capital amendment involving a consolidation of 150 shares into one, followed by a split of one share into 50, effective July 3, 2026. Shareholders with fewer than 150 shares will receive cash compensation of US$1.60 per share instead of participating in the split. The company will continue trading on the Toronto Stock Exchange under the same symbol post-amendment. COSCIENS also plans to suspend its U.S. SEC reporting obligations after the amendment takes effect.
In 2025, AI-related companies raised at least $200 billion in debt to finance data center buildouts, marking one of the largest tech sector financing efforts ever. Financial expert Jim Rickards highlights that much of this debt is held through comple...
Celtic Lux Holdings, formerly Alvogen Lux Holdings, purchased 10,133,333 shares of Alvotech at $3.75 per share on June 16, 2026. This transaction was reported to the Luxembourg financial regulator, CSSF, indicating significant insider activity. The p...
FTI Consulting appointed Jerome Nyssen as Senior Managing Director in its Risk Advisory practice in Australia to enhance AI-driven risk, compliance, and governance services. Nyssen brings 25 years of experience across financial services and technolog...
General Fusion has made significant progress with its LM26 Magnetized Target Fusion machine, achieving plasma electron temperatures of about 8.4 million degrees Celsius (0.72 keV), nearing its 1 keV target. This milestone demonstrates effective plasm...
OpenAI has introduced 'Patch the Planet,' a new initiative partnering with security firm Trail of Bits to help open source projects improve cybersecurity. The program involves security experts reviewing code issues and developing patches with support...
